Merck KGaA (MRK) Given a €80.00 Price Target by Nord/LB Analysts
Merck KGaA (FRA:MRK) has been assigned a €80.00 ($93.02) price target by equities researchers at Nord/LB in a research report issued to clients and investors on Wednesday. The firm presently has a “sell” rating on the healthcare company’s stock. Nord/LB’s price target would indicate a potential downside of 16.65% from the stock’s previous close.
Other analysts have also recently issued research reports about the stock. Kepler Capital Markets set a €106.00 ($123.26) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Thursday, July 26th. Commerzbank set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the company a “buy” rating in a report on Thursday, August 2nd. Sanford C. Bernstein set a €105.00 ($122.09) target price on shares of Merck KGaA and gave the company a “buy” rating in a report on Thursday, August 9th. UBS Group set a €115.00 ($133.72) target price on shares of Merck KGaA and gave the company a “buy” rating in a report on Thursday, August 9th. Finally, Berenberg Bank set a €104.00 ($120.93) target price on shares of Merck KGaA and gave the company a “buy” rating in a report on Thursday, August 9th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have given a buy rating to the company’s stock. Merck KGaA currently has a consensus rating of “Hold” and an average target price of €98.00 ($113.95).
Shares of MRK opened at €95.98 ($111.60) on Wednesday. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: Buyback For Investors Defined
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.